Navigation Links
LCA-Vision Reports on Annual Meeting of Stockholders

CINCINNATI, May 21, 2013 /PRNewswire/ -- LCA-Vision Inc. (NASDAQ: LCAV), a leading provider of laser vision correction services under the LasikPlus® brand, announces that all nominees to the company's Board of Directors were re-elected to one-year terms at today's annual meeting of stockholders.  These Directors are:

  • William F. Bahl , co-founder and President of Bahl & Gaynor Investment Counsel
  • John C. Hassan , consultant with BSC Ventures
  • Edgar F. Heizer III , Chairman of Manus Health Systems, Inc.
  • James C. Wachtman , Chief Executive Officer of Pulse Therapeutics and Venture Partner of SV Life Sciences
  • E. Anthony Woods , non-executive Chairman of the Board of LCA-Vision, and Chairman and Chief Executive Officer of SupportSource, LLC
  • As previously announced, Director John H. Gutfreund , President of Gutfreund & Co. Inc., retired as a Director of the company immediately prior to the meeting.  His position on the Board was not filled and Board membership was reduced to five, each of whom is independent.  Stockholders also approved, by advisory vote, the company's named executive officer compensation and ratified the appointment of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2013.

    Commenting on LCA-Vision's business, Mr. Woods stated, "LCA-Vision is built on a solid foundation as a recognized leader in the laser vision correction industry with a network of LasikPlus® vision centers and a proven business model supported by a strong balance sheet.  I'm proud of our unwavering commitment to providing exceptional clinical outcomes and patient experiences. Importantly, we continue to see a long-term business opportunity in laser vision correction. 

    "That said, our company and our industry are challenged by the prolonged weakness in the U.S. economy, as well as by the federal government's mandate to lower the maximum contribution for medical flexible spending accounts," he added. "In reviewing the issues and opportunities facing our company, the Board and executive management team have developed an action plan with specific priorities aimed at returning our laser vision correction business to sustained profitability, while working to diversify revenue streams and payer mix to mitigate the impact of future economic downturns.  Our plan is focused on enhancing shareholder value and includes fresh approaches to improving our LASIK business, as well as cost controls and investment in our future growth and expansion. 

    "I'd like personally to thank John Gutfreund for his 16 years of service as a valued member of the LCA-Vision Board.  John brought significant expertise and insight into strategic decision-making and finance based on his work as chief executive of several top Wall Street firms, as well as a wealth of experience in corporate governance from his positions on various public company boards," said Mr. Woods.  "We wish him all the best."

    Forward-Looking Statements
    This news release contains forward-looking statements based on current expectations, forecasts and assumptions of LCA-Vision that are subject to risks and uncertainties. The forward-looking statements in this release are based on information available to the company as of the date hereof. Actual results could differ materially from those stated or implied in the forward-looking statements due to risks and uncertainties associated with its business.  In addition to the risk factors discussed in the company's Form 10-K and other filings with the Securities and Exchange Commission, there are a number of other risks and uncertainties associated with its business including, without limitation, the successful execution of cost-effective marketing strategies to drive patients to its vision centers; the impact of low consumer confidence and discretionary spending; competition in the laser vision correction industry; the possibility of adverse outcomes or long-term side effects of laser vision correction and negative publicity regarding laser vision correction; the company's ability to operate profitable vision centers and retain qualified personnel during periods of lower procedure volumes; the company's success in expanding its services into the cataract market; additional regulatory requirements, such as for Medicare, related to cataract; the continued availability of non-recourse third-party financing for its patients on terms similar to what it has paid historically; the company's ability to achieve profitability in its developing cataract business and the future value of revenues financed by the company and its ability to collect on such financings, which will in turn depend on a number of factors, including the consumer credit environment and the company's ability to manage credit risk related to consumer debt, bankruptcies and other credit trends.

    Further, the Food and Drug Administration's (FDA) advisory board on ophthalmic devices currently is reviewing concerns about post-LASIK quality of life matters, and the FDA is recruiting participants for two studies on LASIK outcomes and quality of life. The FDA or another regulatory body could take legal action against the company or others in the laser vision correction industry. The outcome of this review or legal action potentially could impact negatively the acceptance of LASIK. In addition, the acceptance rate of new technologies and our ability to implement successfully new technologies on a national basis create additional risk.

    Except to the extent required under the federal securities laws and the rules and regulations promulgated by the Securities and Exchange Commission, the company assumes no obligation to update the information included in this news release, whether as a result of new information, future events or circumstances, or otherwise.

    About LCA-Vision Inc./LasikPlus®
    LCA-Vision Inc., a leading provider of laser vision correction services, operates 55 LasikPlus® vision centers in the United States:  50 full-service LasikPlus® fixed-site laser vision correction centers and five pre- and post-operative LasikPlus® satellite centers.

    Earning Trust Every Moment; Transforming Lives Every Day.For Additional InformationCompany Contact:Investor Relations Contact:Barb KiseJody CainLCA-Vision Inc.LHA513-792-9292310-691-7100 –

    SOURCE LCA-Vision Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Ceregene Reports Additional Efficacy Data From Parkinsons Disease Phase 2b Study
    2. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
    3. ULURU Inc. Reports First Quarter 2013 Financial Results
    4. 2013 Armada Specialty Pharmacy Summit Reports Record Attendance
    5. Access Pharmaceuticals Reports First Quarter Results
    6. Global Information Online Market Research Portal Provides Complimentary Sample Service for Customers to Preview Reports by Global Industry Analysts
    7. Solos Endoscopy Reports Full Year 2012 Results
    8. Cardium Presents First Quarter 2013 Financial Results And Reports On Recent Developments
    9. VirtualScopics Reports First Quarter 2013 Results
    10. Mast Therapeutics Reports First Quarter 2013 Financial Results
    11. Synthetic Biologics Reports First Quarter 2013 Financial Results
    Post Your Comments:
    (Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
    (Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
    (Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
    Breaking Medicine Technology:
    (Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
    (Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
    (Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
    (Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
    (Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
    Breaking Medicine News(10 mins):